LSE · SCLP.L
Scancell Holdings plc
£0.87-£0.02 (-1.8%)
Scancell Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 70.37% below the high.
Loading market information…
LSE · AVCT.L · GBp
Stock price, earnings
Quote as of Oct 30, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Avacta Group Plc’s quoted price sits in the lower half of its reported 52-week range, 34.24% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Avacta Group Plc’s next earnings report is currently expected on Apr 22, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Avacta Group Plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Avacta Group Plc operates as a clinical-stage biopharmaceutical company, specializing in the development of cancer therapies and diagnostic solutions. These advancements are driven by its proprietary Affimer and pre|CISION technology platforms, with the company's activities spanning the United Kingdom, North America, South Korea, and broader regions of Asia and Europe. Functioning across distinct Diagnostics and Therapeutics segments, Avacta's diagnostic endeavors include crafting bespoke Affimer proteins for customer products, developing internal diagnostic assays such as the AffiDX SARS-CoV-2 rapid antigen test, and supplying Affimer reagents for integration into third-party offerings. Concurrently, its Therapeutics division is dedicated to pioneering novel cancer immunotherapies through the strategic combination of its proprietary technologies. The company maintains a comprehensive network of collaborations, notably including a research partnership focused on its pre|CISION technology, which utilizes a substrate highly sensitive to cleavage by fibroblast activation protein alpha. Further key alliances encompass a drug development collaboration with LG Chem Life Sciences; a strategic partnership with Tufts University School of Medicine to advance Affimer drug conjugate therapies; a licensing agreement with POINT Biopharma Inc. for the creation of tumor-activated radiopharmaceuticals; and a drug development partnership with AffyXell, aimed at developing engineered mesenchymal stem cells for autoimmune disease treatment. Avacta Group Plc was established in 2003 and is headquartered in Wetherby, United Kingdom.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:39 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| £4.14M+96.95% vs estimate |
| Q4 2022 | Sep 29, 2022 | -£0.04 | £5.52M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.87-£0.02 (-1.8%)
Scancell Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 70.37% below the high.
£0.32£0.00 (0.0%)
Faron Pharmaceuticals Oy’s quoted price sits in the lower half of its reported 52-week range, 85.0% below the high.
£0.83£0.00 (0.0%)
Arecor Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 13.16% below the high.
£0.15£0.00 (0.0%)
Sareum Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 61.88% below the high.
£0.03-£0.01 (-16.67%)
ImmuPharma PLC’s quoted price sits in the lower half of its reported 52-week range, 72.57% below the high.
£0.01£0.00 (0.0%)
Thalia Therapeutics Plc’s quoted price sits in the lower half of its reported 52-week range, 39.47% below the high.
£0.00-£0.00 (-2.86%)
Theracryf Plc’s quoted price sits in the lower half of its reported 52-week range, 36.57% below the high.
£0.09£0.00 (0.0%)
CRISM Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.7% below the high.
